Pasireotide vs Somatropin
Overview
Pasireotide and Somatropin are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Pasireotide and Somatropin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Pasireotide | Somatropin | |
|---|---|---|
| Category | Hormonal | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) | 0.16-0.24 mg/kg/week (pediatric growth hormone deficiency); about 0.2 mg/day (adult growth hormone deficiency) |
| Frequency | Twice daily (SC formulation) or every 4 weeks (LAR formulation) | daily subcutaneous injection |
| Reported benefits | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism | In labeled use, somatropin increases linear growth in children with growth failure from growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, small size for gestational age and idiopathic short stature. In adults with diagnosed growth hormone deficiency, professional guidelines describe benefits in body composition, exercise capacity, skeletal integrity and quality-of-life measures, with the largest benefit in the most severely deficient patients. |
| Reported side effects | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) | Fluid retention, edema, arthralgia and carpal tunnel syndrome are common in adults. Labeled warnings include glucose intolerance and new-onset diabetes, intracranial hypertension, slipped capital femoral epiphysis and scoliosis progression in children, hypothyroidism, hypoadrenalism, pancreatitis and hypersensitivity reactions. |
Key differences
Primary use. Pasireotide is categorised under Hormonal, while Somatropin falls under Hormonal. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Pasireotide: FDA-approved. Somatropin: FDA-approved.
Dosing. Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)). Somatropin is typically dosed at 0.16-0.24 mg/kg/week (pediatric growth hormone deficiency); about 0.2 mg/day (adult growth hormone deficiency) (daily subcutaneous injection).
Can you stack them?
Some protocols combine peptides, but stacking Pasireotide and Somatropin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Pasireotide and Somatropin?
- Pasireotide and Somatropin are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status. Pasireotide is FDA-approved for one or more indications, whereas Somatropin is FDA-approved for one or more indications.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- What is Somatropin used for?
- Recombinant human growth hormone, FDA-approved for growth failure in children and growth hormone deficiency in adults.
- Can you take Pasireotide and Somatropin together?
- Some users combine peptides within a single protocol, but stacking Pasireotide and Somatropin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Pasireotide or Somatropin FDA-approved?
- Pasireotide is FDA-approved for one or more indications. Somatropin is FDA-approved for one or more indications.
Read the full articles
- Pasireotide — full monograph: mechanism, research, dosing & references
- Somatropin — full monograph: mechanism, research, dosing & references